EiRx: Potential new therapies for colorectal and other cancers
EiRx Therapeutics plc announced the filing of patent applications describing new drug candidates with potential value as treatments for a range of cancers including colorectal and breast tumours.
EiRx scientists used the company's proprietary ALIBITM and EnPADTM technologies to target APC--catenin signalling, a cellular control pathway known to play a major role in the majority of cases of colorectal cancer, as well as in several other tumour types. A custom-designed EnPADTM cell line was used to screen a focused library of drug-like, kinase inhibitor compounds, resulting in the discovery of a series of related compounds with selective activity against transformed cell types including colorectal and breast cancer cell lines. The company has now submitted patent applications to protect these novel therapeutic candidates in key global markets. The EnPADTM technology development programme was funded in part by the Marie Curie Transfer Of Knowledge grant awarded to the company in late 2004.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
